{
    "markdown": "<a id='1b683e50-5f49-46e5-86dc-fc65093a8a2b'></a>\n\n12. CONTENTS OF APPLICATION\nThis application contains the following items: (Check all that apply)\n\noption 1. Form FDA 1571 [21 CFR 312.23(a)(1)]: [x]\noption 2. Table of Contents (21 CFR 312.23(a)(2)): [ ]\noption 3. Introductory statement (21 CFR 312.23(a)(3)): [ ]\noption 4. General Investigational plan (21 CFR 312.23(a)(3)): [ ]\noption 5. Investigator's brochure (21 CFR 312.23(a)(5)): [ ]\noption 6. Protocol(s) [21 CFR 312.23(a)(6)]: [ ]\n  option a. Study protocol(s) (21 CFR 312.23(a)(6)): [ ]\n  option b. Investigator data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572: [ ]\n  option c. Facilities data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572: [ ]\n  option d. Institutional Review Board data (21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572: [ ]\noption 7. Chemistry, manufacturing, and control data (21 CFR 312.23(a)(7)): [ ]\n  option Environmental assessment or claim for exclusion (21 CFR 312.23(e)(7)(iv)(e)): [ ]\noption 8. Pharmacology and toxicology data [21 CFR 312.23(a)(8)]: [ ]\noption 9. Previous human experience [21 CFR 312.23(a)(9)]: [ ]\noption 10. Additional information (21 CFR 312.23(a)(10)]: [ ]\n\n13. IS ANY PART OF THE CLINICAL STUDY TO BE CONDUCTED BY A CONTRACT RESEARCH ORGANIZATION? option YES: [ ] option NO: [ ]\nIF YES, WILL ANY SPONSOR OBLIGATIONS BE TRANSFERRED TO THE CONTRACT RESEARCH ORGANIZATION? option YES: [ ] option NO: [ ]\nIF YES, ATTACH A STATEMENT CONTAINING THE NAME AND ADDRESS OF THE CONTRACT RESEARCH ORGANIZATION, IDENTIFICATION OF THE CLINICAL STUDY, AND A LISTING OF THE OBLIGATIONS TRANSFERRED.\n\n14. NAME AND TITLE OF THE PERSON RESPONSIBLE FOR MONITORING THE CONDUCT AND PROGRESS OF THE CLINICAL INVESTIGATIONS\nN/A\n\n15. NAME(S) AND TITLE(S) OF THE PERSON(S) RESPONSIBLE FOR REVIEW AND EVALUATION OF INFORMATION RELEVANT TO THE SAFETY OF THE DRUG\nN/A\n\nI agree not to begin clinical investigations until 30 days after FDA's receipt of the IND unless I receive earlier notification by FDA that the studies may begin. I also agree not to begin or continue clinical investigations covered by the IND if those studies are placed on clinical hold. I agree that an Institutional Review Board (IRB) that complies with the requirements set fourth In 21 CFR Part 56 will be responsible for Initial and continuing review and approval of each of the studies in the proposed clinical investigation. I agree to conduct the investigation in accordance with all other applicable regulatory requirements.\n\n16. NAME OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE\nJanet L. Haskins\n\n17. SIGNATURE OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE\n<::attestation: Signature\nSigned\nSignature: legible\nShort description of visual elements and positioning: A handwritten signature is present on the right side, next to item 16.::>\n\n18. ADDRESS (Number, Street, City, State and Zip Code)\n475 Half Day Road, Suite 500\nLincolnshire, IL 60069\n\n19. TELEPHONE NUMBER (Include Area Code)\n847-383-3243\n\n20. DATE\n11/18/02\n\n<a id='c5cf8aff-92b9-4d6a-9e18-7ae6856b72f3'></a>\n\n(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18. Sec. 1001.)\n\nPublic reporting burden for this collection of information is estimated to average 100 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing reviewing the collection of Information. Send comments regarding this burden estimate or any other aspect of this collection of Information, including suggestions for reducing this burden to:\n\nFood and Drug Administration\nCBER (HFM-90)\n1401 Rockville Pike\nRockville, MD 20852-1448\n\nFood and Drug Administration\nCDER (HFD-94)\n12229 Wilkins Avenue\nRockville, MD 20852\n\n\"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.\"\n\nPlease DO NOT RETURN this application to this address.\n...\n\n\n<a id='276a1570-4729-43e3-8601-98de44274f1d'></a>\n\nFORM FDA 1571 (9/02)\n\n<a id='10ecfc86-aade-4c57-9cad-bfeca8775a7d'></a>\n\nPREVIOUS EDITION IS OBSOLETE.\n\n<a id='87af5515-f7c3-4ddf-924e-eda36b032ed2'></a>\n\nPAGE 2 OF 2\nPSC Multi-Age Branch (30) v. 4.1.1002 - RP\n\n<a id='92220a0b-ff43-46ab-9af0-b445e183a1ad'></a>\n\nConfidential -- Subject to Protective Order\n\n<a id='52764bf5-8cd8-4d4e-9ef0-ca320060c6e0'></a>\n\nTAK-INDNDA-01273550\nProduced in MDL on 09/11/2012\n\n<a id='86c1ee0f-77c8-4ebc-802e-c74147317623'></a>\n\nSource: https://www.industrydocuments.ucsf.edu/docs/gyjf0226 P167100004",
    "chunks": [
        {
            "markdown": "<a id='1b683e50-5f49-46e5-86dc-fc65093a8a2b'></a>\n\n12. CONTENTS OF APPLICATION\nThis application contains the following items: (Check all that apply)\n\noption 1. Form FDA 1571 [21 CFR 312.23(a)(1)]: [x]\noption 2. Table of Contents (21 CFR 312.23(a)(2)): [ ]\noption 3. Introductory statement (21 CFR 312.23(a)(3)): [ ]\noption 4. General Investigational plan (21 CFR 312.23(a)(3)): [ ]\noption 5. Investigator's brochure (21 CFR 312.23(a)(5)): [ ]\noption 6. Protocol(s) [21 CFR 312.23(a)(6)]: [ ]\n  option a. Study protocol(s) (21 CFR 312.23(a)(6)): [ ]\n  option b. Investigator data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572: [ ]\n  option c. Facilities data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572: [ ]\n  option d. Institutional Review Board data (21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572: [ ]\noption 7. Chemistry, manufacturing, and control data (21 CFR 312.23(a)(7)): [ ]\n  option Environmental assessment or claim for exclusion (21 CFR 312.23(e)(7)(iv)(e)): [ ]\noption 8. Pharmacology and toxicology data [21 CFR 312.23(a)(8)]: [ ]\noption 9. Previous human experience [21 CFR 312.23(a)(9)]: [ ]\noption 10. Additional information (21 CFR 312.23(a)(10)]: [ ]\n\n13. IS ANY PART OF THE CLINICAL STUDY TO BE CONDUCTED BY A CONTRACT RESEARCH ORGANIZATION? option YES: [ ] option NO: [ ]\nIF YES, WILL ANY SPONSOR OBLIGATIONS BE TRANSFERRED TO THE CONTRACT RESEARCH ORGANIZATION? option YES: [ ] option NO: [ ]\nIF YES, ATTACH A STATEMENT CONTAINING THE NAME AND ADDRESS OF THE CONTRACT RESEARCH ORGANIZATION, IDENTIFICATION OF THE CLINICAL STUDY, AND A LISTING OF THE OBLIGATIONS TRANSFERRED.\n\n14. NAME AND TITLE OF THE PERSON RESPONSIBLE FOR MONITORING THE CONDUCT AND PROGRESS OF THE CLINICAL INVESTIGATIONS\nN/A\n\n15. NAME(S) AND TITLE(S) OF THE PERSON(S) RESPONSIBLE FOR REVIEW AND EVALUATION OF INFORMATION RELEVANT TO THE SAFETY OF THE DRUG\nN/A\n\nI agree not to begin clinical investigations until 30 days after FDA's receipt of the IND unless I receive earlier notification by FDA that the studies may begin. I also agree not to begin or continue clinical investigations covered by the IND if those studies are placed on clinical hold. I agree that an Institutional Review Board (IRB) that complies with the requirements set fourth In 21 CFR Part 56 will be responsible for Initial and continuing review and approval of each of the studies in the proposed clinical investigation. I agree to conduct the investigation in accordance with all other applicable regulatory requirements.\n\n16. NAME OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE\nJanet L. Haskins\n\n17. SIGNATURE OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE\n<::attestation: Signature\nSigned\nSignature: legible\nShort description of visual elements and positioning: A handwritten signature is present on the right side, next to item 16.::>\n\n18. ADDRESS (Number, Street, City, State and Zip Code)\n475 Half Day Road, Suite 500\nLincolnshire, IL 60069\n\n19. TELEPHONE NUMBER (Include Area Code)\n847-383-3243\n\n20. DATE\n11/18/02",
            "type": "text",
            "id": "1b683e50-5f49-46e5-86dc-fc65093a8a2b",
            "grounding": {
                "box": {
                    "left": 0.06133261322975159,
                    "top": 0.04377672076225281,
                    "right": 0.9164208173751831,
                    "bottom": 0.7442406415939331
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='c5cf8aff-92b9-4d6a-9e18-7ae6856b72f3'></a>\n\n(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18. Sec. 1001.)\n\nPublic reporting burden for this collection of information is estimated to average 100 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing reviewing the collection of Information. Send comments regarding this burden estimate or any other aspect of this collection of Information, including suggestions for reducing this burden to:\n\nFood and Drug Administration\nCBER (HFM-90)\n1401 Rockville Pike\nRockville, MD 20852-1448\n\nFood and Drug Administration\nCDER (HFD-94)\n12229 Wilkins Avenue\nRockville, MD 20852\n\n\"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.\"\n\nPlease DO NOT RETURN this application to this address.\n...\n",
            "type": "text",
            "id": "c5cf8aff-92b9-4d6a-9e18-7ae6856b72f3",
            "grounding": {
                "box": {
                    "left": 0.06555664539337158,
                    "top": 0.734319806098938,
                    "right": 0.916113018989563,
                    "bottom": 0.867483377456665
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='276a1570-4729-43e3-8601-98de44274f1d'></a>\n\nFORM FDA 1571 (9/02)",
            "type": "text",
            "id": "276a1570-4729-43e3-8601-98de44274f1d",
            "grounding": {
                "box": {
                    "left": 0.06719028204679489,
                    "top": 0.8786003589630127,
                    "right": 0.21293163299560547,
                    "bottom": 0.8989568948745728
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='10ecfc86-aade-4c57-9cad-bfeca8775a7d'></a>\n\nPREVIOUS EDITION IS OBSOLETE.",
            "type": "text",
            "id": "10ecfc86-aade-4c57-9cad-bfeca8775a7d",
            "grounding": {
                "box": {
                    "left": 0.3908901810646057,
                    "top": 0.8785709142684937,
                    "right": 0.5846806764602661,
                    "bottom": 0.8985123634338379
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='87af5515-f7c3-4ddf-924e-eda36b032ed2'></a>\n\nPAGE 2 OF 2\nPSC Multi-Age Branch (30) v. 4.1.1002 - RP",
            "type": "text",
            "id": "87af5515-f7c3-4ddf-924e-eda36b032ed2",
            "grounding": {
                "box": {
                    "left": 0.7559956312179565,
                    "top": 0.8791002631187439,
                    "right": 0.9185777902603149,
                    "bottom": 0.9060099720954895
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='92220a0b-ff43-46ab-9af0-b445e183a1ad'></a>\n\nConfidential -- Subject to Protective Order",
            "type": "marginalia",
            "id": "92220a0b-ff43-46ab-9af0-b445e183a1ad",
            "grounding": {
                "box": {
                    "left": 0.047477319836616516,
                    "top": 0.9200742244720459,
                    "right": 0.3307362198829651,
                    "bottom": 0.9414898157119751
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='52764bf5-8cd8-4d4e-9ef0-ca320060c6e0'></a>\n\nTAK-INDNDA-01273550\nProduced in MDL on 09/11/2012",
            "type": "text",
            "id": "52764bf5-8cd8-4d4e-9ef0-ca320060c6e0",
            "grounding": {
                "box": {
                    "left": 0.720297634601593,
                    "top": 0.9170862436294556,
                    "right": 0.9400586485862732,
                    "bottom": 0.9493105411529541
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='86c1ee0f-77c8-4ebc-802e-c74147317623'></a>\n\nSource: https://www.industrydocuments.ucsf.edu/docs/gyjf0226 P167100004",
            "type": "marginalia",
            "id": "86c1ee0f-77c8-4ebc-802e-c74147317623",
            "grounding": {
                "box": {
                    "left": 0.21897029876708984,
                    "top": 0.9771826267242432,
                    "right": 0.7828949689865112,
                    "bottom": 1.0000001192092896
                },
                "page": 0
            }
        }
    ],
    "splits": [
        {
            "class": "full",
            "identifier": "full",
            "pages": [
                0
            ],
            "markdown": "<a id='1b683e50-5f49-46e5-86dc-fc65093a8a2b'></a>\n\n12. CONTENTS OF APPLICATION\nThis application contains the following items: (Check all that apply)\n\noption 1. Form FDA 1571 [21 CFR 312.23(a)(1)]: [x]\noption 2. Table of Contents (21 CFR 312.23(a)(2)): [ ]\noption 3. Introductory statement (21 CFR 312.23(a)(3)): [ ]\noption 4. General Investigational plan (21 CFR 312.23(a)(3)): [ ]\noption 5. Investigator's brochure (21 CFR 312.23(a)(5)): [ ]\noption 6. Protocol(s) [21 CFR 312.23(a)(6)]: [ ]\n  option a. Study protocol(s) (21 CFR 312.23(a)(6)): [ ]\n  option b. Investigator data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572: [ ]\n  option c. Facilities data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572: [ ]\n  option d. Institutional Review Board data (21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572: [ ]\noption 7. Chemistry, manufacturing, and control data (21 CFR 312.23(a)(7)): [ ]\n  option Environmental assessment or claim for exclusion (21 CFR 312.23(e)(7)(iv)(e)): [ ]\noption 8. Pharmacology and toxicology data [21 CFR 312.23(a)(8)]: [ ]\noption 9. Previous human experience [21 CFR 312.23(a)(9)]: [ ]\noption 10. Additional information (21 CFR 312.23(a)(10)]: [ ]\n\n13. IS ANY PART OF THE CLINICAL STUDY TO BE CONDUCTED BY A CONTRACT RESEARCH ORGANIZATION? option YES: [ ] option NO: [ ]\nIF YES, WILL ANY SPONSOR OBLIGATIONS BE TRANSFERRED TO THE CONTRACT RESEARCH ORGANIZATION? option YES: [ ] option NO: [ ]\nIF YES, ATTACH A STATEMENT CONTAINING THE NAME AND ADDRESS OF THE CONTRACT RESEARCH ORGANIZATION, IDENTIFICATION OF THE CLINICAL STUDY, AND A LISTING OF THE OBLIGATIONS TRANSFERRED.\n\n14. NAME AND TITLE OF THE PERSON RESPONSIBLE FOR MONITORING THE CONDUCT AND PROGRESS OF THE CLINICAL INVESTIGATIONS\nN/A\n\n15. NAME(S) AND TITLE(S) OF THE PERSON(S) RESPONSIBLE FOR REVIEW AND EVALUATION OF INFORMATION RELEVANT TO THE SAFETY OF THE DRUG\nN/A\n\nI agree not to begin clinical investigations until 30 days after FDA's receipt of the IND unless I receive earlier notification by FDA that the studies may begin. I also agree not to begin or continue clinical investigations covered by the IND if those studies are placed on clinical hold. I agree that an Institutional Review Board (IRB) that complies with the requirements set fourth In 21 CFR Part 56 will be responsible for Initial and continuing review and approval of each of the studies in the proposed clinical investigation. I agree to conduct the investigation in accordance with all other applicable regulatory requirements.\n\n16. NAME OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE\nJanet L. Haskins\n\n17. SIGNATURE OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE\n<::attestation: Signature\nSigned\nSignature: legible\nShort description of visual elements and positioning: A handwritten signature is present on the right side, next to item 16.::>\n\n18. ADDRESS (Number, Street, City, State and Zip Code)\n475 Half Day Road, Suite 500\nLincolnshire, IL 60069\n\n19. TELEPHONE NUMBER (Include Area Code)\n847-383-3243\n\n20. DATE\n11/18/02\n\n<a id='c5cf8aff-92b9-4d6a-9e18-7ae6856b72f3'></a>\n\n(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18. Sec. 1001.)\n\nPublic reporting burden for this collection of information is estimated to average 100 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing reviewing the collection of Information. Send comments regarding this burden estimate or any other aspect of this collection of Information, including suggestions for reducing this burden to:\n\nFood and Drug Administration\nCBER (HFM-90)\n1401 Rockville Pike\nRockville, MD 20852-1448\n\nFood and Drug Administration\nCDER (HFD-94)\n12229 Wilkins Avenue\nRockville, MD 20852\n\n\"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.\"\n\nPlease DO NOT RETURN this application to this address.\n...\n\n\n<a id='276a1570-4729-43e3-8601-98de44274f1d'></a>\n\nFORM FDA 1571 (9/02)\n\n<a id='10ecfc86-aade-4c57-9cad-bfeca8775a7d'></a>\n\nPREVIOUS EDITION IS OBSOLETE.\n\n<a id='87af5515-f7c3-4ddf-924e-eda36b032ed2'></a>\n\nPAGE 2 OF 2\nPSC Multi-Age Branch (30) v. 4.1.1002 - RP\n\n<a id='92220a0b-ff43-46ab-9af0-b445e183a1ad'></a>\n\nConfidential -- Subject to Protective Order\n\n<a id='52764bf5-8cd8-4d4e-9ef0-ca320060c6e0'></a>\n\nTAK-INDNDA-01273550\nProduced in MDL on 09/11/2012\n\n<a id='86c1ee0f-77c8-4ebc-802e-c74147317623'></a>\n\nSource: https://www.industrydocuments.ucsf.edu/docs/gyjf0226 P167100004",
            "chunks": [
                "1b683e50-5f49-46e5-86dc-fc65093a8a2b",
                "c5cf8aff-92b9-4d6a-9e18-7ae6856b72f3",
                "276a1570-4729-43e3-8601-98de44274f1d",
                "10ecfc86-aade-4c57-9cad-bfeca8775a7d",
                "87af5515-f7c3-4ddf-924e-eda36b032ed2",
                "92220a0b-ff43-46ab-9af0-b445e183a1ad",
                "52764bf5-8cd8-4d4e-9ef0-ca320060c6e0",
                "86c1ee0f-77c8-4ebc-802e-c74147317623"
            ]
        }
    ],
    "grounding": {
        "1b683e50-5f49-46e5-86dc-fc65093a8a2b": {
            "box": {
                "left": 0.06133261322975159,
                "top": 0.04377672076225281,
                "right": 0.9164208173751831,
                "bottom": 0.7442406415939331
            },
            "page": 0,
            "type": "chunkText"
        },
        "c5cf8aff-92b9-4d6a-9e18-7ae6856b72f3": {
            "box": {
                "left": 0.06555664539337158,
                "top": 0.734319806098938,
                "right": 0.916113018989563,
                "bottom": 0.867483377456665
            },
            "page": 0,
            "type": "chunkText"
        },
        "276a1570-4729-43e3-8601-98de44274f1d": {
            "box": {
                "left": 0.06719028204679489,
                "top": 0.8786003589630127,
                "right": 0.21293163299560547,
                "bottom": 0.8989568948745728
            },
            "page": 0,
            "type": "chunkText"
        },
        "10ecfc86-aade-4c57-9cad-bfeca8775a7d": {
            "box": {
                "left": 0.3908901810646057,
                "top": 0.8785709142684937,
                "right": 0.5846806764602661,
                "bottom": 0.8985123634338379
            },
            "page": 0,
            "type": "chunkText"
        },
        "87af5515-f7c3-4ddf-924e-eda36b032ed2": {
            "box": {
                "left": 0.7559956312179565,
                "top": 0.8791002631187439,
                "right": 0.9185777902603149,
                "bottom": 0.9060099720954895
            },
            "page": 0,
            "type": "chunkText"
        },
        "92220a0b-ff43-46ab-9af0-b445e183a1ad": {
            "box": {
                "left": 0.047477319836616516,
                "top": 0.9200742244720459,
                "right": 0.3307362198829651,
                "bottom": 0.9414898157119751
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "52764bf5-8cd8-4d4e-9ef0-ca320060c6e0": {
            "box": {
                "left": 0.720297634601593,
                "top": 0.9170862436294556,
                "right": 0.9400586485862732,
                "bottom": 0.9493105411529541
            },
            "page": 0,
            "type": "chunkText"
        },
        "86c1ee0f-77c8-4ebc-802e-c74147317623": {
            "box": {
                "left": 0.21897029876708984,
                "top": 0.9771826267242432,
                "right": 0.7828949689865112,
                "bottom": 1.0000001192092896
            },
            "page": 0,
            "type": "chunkMarginalia"
        }
    },
    "metadata": {
        "filename": "gyjf0226_4.png",
        "org_id": null,
        "page_count": 1,
        "duration_ms": 9239,
        "credit_usage": 3.0,
        "job_id": "hxalpththalrbomuup8u22c6r",
        "version": "dpt-2-20250919"
    }
}